Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

NCT03838926 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.

NCT NCT03838926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03838926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Vanda Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
September 27, 2018
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory hematologic malignancies